JBIO — Jade Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1798749 ·
Last close
$15.40
Market Cap
$979.40M
52W High
$28.00
52W Low
$11.02
ADV30
954,942
Next earnings
2026-11-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -39,640,000 | -35,055,000 | 486,391,000 | 80,386,000 | 30,887,000 |
| Jun 2026 | 0 | — | -58,916,000 | -55,765,000 | 472,113,000 | 107,250,000 | 32,198,000 |
| Mar 2026 | 0 | — | -43,445,000 | -40,368,000 | 319,433,000 | 55,085,000 | 22,971,000 |
| Dec 2025 | 0 | — | -34,979,000 | -31,932,000 | 349,781,000 | 88,438,000 | 17,263,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-123,510,000
Investing CF
$-352,972,000
Financing CF
$362,888,000
CapEx
$-60,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.67
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-270,522,000
Inventory
—
Receivables
—
ST Investments
$353,955,000
EBIT TTM
$-164,741,000
Pretax Income TTM
$-153,151,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -113,542,000 | -127,410,000 | 349,781,000 | 17,263,000 | 332,518,000 | -94,689,000 |
| Dec 2024 | — | — | — | 72,799,000 | 119,598,000 | -46,799,000 | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-188,891,000
OpCashFlow TTM
—
Assets (Latest)
$472,113,000
Forward EPS
$-2.26
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $20.00 · spot: $15.49 · call volume: 5 · put volume: 1Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPTX | Seaport Therapeutics, Inc. | $972.65M | $18.17 | — |
| SVRA | Savara Inc | $988.39M | $4.48 | — |
| ANRO | Alto Neuroscience, Inc. | $999.16M | $24.91 | — |
| CYRX | Cryoport, Inc. | $999.81M | $19.74 | — |
| MLTX | MoonLake Immunotherapeutics | $957.45M | $11.25 | — |
News headlines (Yahoo Finance, 1h cache)
Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-13 12:00 · Yahoo
Jade Biosciences to Participate in Upcoming Conferences
2026-11-03 12:00 · Yahoo
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
2026-10-21 11:00 · Yahoo
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
2026-09-30 11:00 · Yahoo
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
2026-06-30 13:21 · Yahoo
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
2026-06-26 11:00 · Yahoo
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-06-05 20:01 · Yahoo
Jade Biosciences Announces Pricing of Public Offering of Common Stock
2026-06-04 02:58 · Yahoo
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
2026-06-01 11:00 · Yahoo
Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
2026-06-02 01:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.